VO659 Earns Orphan Drug Designation

VO659 Earns Orphan Drug Designation

302386

VO659 Earns Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Vico Therapeutics’ VO659, an investigational antisense oligonucleotide gene-silencing therapy for Huntington’s disease. “We are delighted that FDA has granted this orphan-drug designation,” Rupert Sandbrink, MD, PhD, chief medical officer of VICO, said in a press release. “This is affirmation of the potential of our AON [antisense oligonucleotide] approach.” Huntington’s disease is caused by mutations in the huntingtin (HTT) gene, which expand the…

You must be logged in to read/download the full post.